Pfizer's Lipitor revenue worldwide 2003-2018

During 2018, Pfizer’s Lipitor generated nearly 2.1 billion U.S. dollars of revenue. This was the second year in a row with a reported increase after the record-low in 2016, with revenues of 1.76 billion dollars. For around a decade cholesterol-lowering drug Lipitor was one of the company’s top blockbusters, with record-high revenues of approximately 13 billion U.S. dollars in 2006. In the year of patent loss – 2011 – Lipitor still generated roughly 10 billion dollars, before a heavy drop down to four billion dollars in 2012.

Pharmaceutical company Pfizer

Drug manufacturer Pfizer is headquartered in Midtown Manhattan, New York City. At this moment, it is the world’s leading pharmaceutical company based on pharmaceutical sales of prescribed and over-the-counter drugs. Today, the company is focused on human medicine, divided into two major segments - Innovative Health and Essential Health. However, until 2013 the company also had a notable animal health division which was spun-off and today is known as Zoetis.

Facts about Lipitor/atorvastatin

Lipitor was approved by the FDA (Food and Drug Administration) in 1996 for medical use. Since its patent protection expired in 2011, it is now also sold under its generic name atorvastatin. Today, atorvastatin is one of the most prescribed drugs in the United States. The drug is primarily used as prevention for people with a high risk for developing cardiovascular diseases and as a treatment for abnormal lipid levels (dyslipidemia). Generic versions of Lipitor lead to annual savings in drug spending of around 16 billion U.S. dollars.

Worldwide revenue of Pfizer's Lipitor from 2003 to 2018

Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

February 2019

Region

Worldwide

Survey time period

2003 to 2018

Supplementary notes

This statistic was assembled from several of Pfizer's annual and financial reports.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pfizer"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.